# Apixaban

## ELIQUIS 5mg

| 藥物代碼           | OELI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), w/ >=1 risk factors [eg, prior stroke or transient ischaemic attack, age >=75 yr, HTN, DM, symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.                                                                                                                                                                                                                                                                                                                                                                     |
| 副作用             | Epistaxis, anaemia, nausea, contusion, haematuria, haematoma, vag & urethral haemorrhage; eye, GI & rectal haemorrhage; gingival bleeding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 禁忌               | Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Lesion or condition at significant risk of major bleeding (eg, current or recent GI ulceration, presence of malignant neoplasms at high risk of bleeding; recent brain/spinal injury, brain/spinal/ophth surgery, intracranial haemorrhage; known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulant eg, unfractionated heparin (UFH), low molecular wt heparins, heparin derivatives, oral anticoagulants except under the circumstances of switching therapy to or from apixaban or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter. |
| 懷孕用藥危分級     | 可能安全                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 孕期用藥建議       | No (Limited) Human Data - animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 附帶說明           | 上方欄位懷孕用藥危險分級藥品 B 級的參考依據為藥品仿單。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity(Mother) 無(很少)資料 - 避免使用(母體)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 注射劑給藥建議途徑 | AC, AC15, PC, PO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 注意事項           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

## Eliquis 2.5mg film-coated

| 藥物代碼           | OELI2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), w/ >=1 risk factors [eg, prior stroke or transient ischaemic attack, age >=75 yr, HTN, DM, symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 副作用             | Epistaxis, anaemia, nausea, contusion, haematuria, haematoma, vag & urethral haemorrhage; eye, GI & rectal haemorrhage; gingival bleeding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 禁忌               | Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Lesion or condition at significant risk of major bleeding (eg, current or recent GI ulceration, presence of malignant neoplasms at high risk of bleeding; recent brain/spinal injury, brain/spinal/ophth surgery, intracranial haemorrhage; known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulant eg, unfractionated heparin (UFH), low molecular wt heparins, heparin derivatives, oral anticoagulants except under the circumstances of switching therapy to or from apixaban or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter.                                                                                                                                                                                          |
| 懷孕用藥危分級     | 尚未確立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 孕期用藥建議       | No (Limited) Human Data - animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 附帶說明           | No Human Data - Potential Risk. [仿單]關於孕婦使用ELIQUIS的可用資料有限，不足以顯示與藥物相關的重大先天缺陷、流產或不良發育結果風險。 使用本品治療可能會增加懷孕與生產期間的出血風險。在動物繁殖試驗中，於器官形成期間分別給予大鼠（口服）、兔子（靜脈注射）及小鼠（口服）相當於人類未結合apixaban曝藥量分？為4、1及19倍劑量，未觀察到apixaban具有對發育的不良影響。 目前尚不清楚指定族群重大先天缺陷和流產的估計背景風險。所有懷孕皆有先天缺陷、流產或其他不良結果的背景風險。在美國一般族群中，臨床公認的懷孕重大先天缺陷和流產估計背景風險分？為2%至4%和15%至20%。 臨床考量 與疾病相關的母體和/或胚胎/胎兒風險 懷孕會增加血栓栓塞的風險，對於具有潛在血栓栓塞性疾病和特定高妊娠的婦女來說，血栓栓塞的風險更高。已發表的資料顯示，先前具有血栓形成病史的女性在懷孕期間有很高的復發風險。 胎兒/新生兒不良反應 使用包括ELIQUIS的抗凝血，可能會增加胎兒和新生兒出血的風險。 分娩或生產 所有接受抗凝血劑治療的病人（包括孕婦），都有出血的風險。 接受椎管？麻醉的女性中，在分娩或生產期間使用 ELIQUIS可能會導致硬脊膜外或脊髓血腫。可考慮於生產期間使用更短效的抗凝血劑 |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 附帶說明           | [仿單] 目前沒有關於人類乳汁中apixaban或其代謝產物的存在，對母乳餵哺孩子或對泌乳量影響的資料。 Apixaban和/或其代謝產物存在於大鼠乳汁中。 由於尚不清楚人類是否會透過乳汁接藥物，因此接受ELIQUIS治療期不建議母乳餵哺。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 注射劑給藥建議途徑 | AC, AC15, PC, PO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 注意事項           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

